Search

everythinglearnresearchcommunity

for

Search:↓

Highly active but fewer CD14+CD16- monocytes are found in Alopecia Areata patients, regardless of severity.

A new diagnostic model can help better diagnose and understand Alopecia Areata.

Autoimmune Polyendocrine Syndromes involve specific combinations of endocrine and non-endocrine autoimmune diseases.

JAK inhibitors may help treat alopecia areata by reversing hair loss.

A simple test can help diagnose a rare bruising disorder after ruling out other causes.

CD3+ T-cell presence is a reliable marker to tell apart alopecia areata from pattern hair loss.

Alopecia areata patients show unique protein activity patterns, suggesting imbalanced signaling pathways.

Biopsy can differentiate between alopecia areata and androgenic alopecia, and if more information is needed, testing for CD3 and CD8 can help.

Higher levels of IL-1a and IL-1RA were found in severe alopecia areata cases.

Alopecia patients have a higher risk of heart disease.

Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.

Genetic screening is crucial for accurately diagnosing APS-1 due to its varied symptoms.

Blood tests can help understand the genetic differences in people with alopecia areata, including how severe it is and if it's inherited.

CD8+ T cells re-expressing CD45RA may predict treatment resistance in severe alopecia areata.

Distinguishing drug-induced lupus from systemic lupus is challenging and requires careful monitoring.

Tofacitinib helped most patients with alopecia areata regrow hair and changes in immune cells were linked to the treatment's effectiveness.

A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.

Ritlecitinib significantly improves scalp hair regrowth in alopecia areata patients over time.

Alopecia areata is rare in organ transplant patients and may be linked to the drug tacrolimus.

Hydroxychloroquine may cause false results in tuberculosis tests for patients with autoimmune skin diseases.

An 84-year-old man developed severe anemia after his first COVID-19 vaccine shot, improved with treatment, and was advised against a second dose.

Leflunomide may lower alopecia areata risk, while other immunomodulators might increase it.

Oral tofacitinib has a moderate success rate and is generally safe for treating hair loss in some patients.

People with alopecia areata are more likely to have other immune-related conditions.

Cell-based therapy using specific immune cells may help treat alopecia areata by promoting hair regrowth.

Increasing Treg cells in the skin does not cure hair loss from alopecia areata in mice.

Nonimmunogenic forms of keratins K71 and K31 can delay and prevent alopecia areata.